Impurity Profile Study of Venlafaxine Hydrochloride, an Antipsychotic Drug Substance
摘要:
Venlafaxine hydrochloride is a phenyl ethylamine derivative, used for the treatment of depression. During the process development of venlafaxine hydrochloride, six process-related potential impurities were detected in high-performance liquid chromatography. All these impurities were identified, synthesized, and subsequently characterized by their respective spectral data (IR, mass, 1H NMR, and 13C NMR) as described in this article.
Impurity Profile Study of Venlafaxine Hydrochloride, an Antipsychotic Drug Substance
摘要:
Venlafaxine hydrochloride is a phenyl ethylamine derivative, used for the treatment of depression. During the process development of venlafaxine hydrochloride, six process-related potential impurities were detected in high-performance liquid chromatography. All these impurities were identified, synthesized, and subsequently characterized by their respective spectral data (IR, mass, 1H NMR, and 13C NMR) as described in this article.
[EN] PROCESS FOR THE PREPARATION OF DESVENLAFAXINE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF<br/>[FR] PROCÉDÉ DE PRÉPARATION DE LA DESVENLAFAXINE ET SELS D'ADDITION D'ACIDE DE CELLE-CI PHARMACEUTIQUEMENT ACCEPTABLES
申请人:CHEMO IBERICA SA
公开号:WO2010079046A1
公开(公告)日:2010-07-15
The present invention relates to a process for the preparation of desvenlafaxine or a pharmaceutically acceptable acid addition salt thereof, based on the demethylation of venlafaxine by the use of alkyl aluminium or alkyl aluminium hydride compounds, particularly TIBA and DIBAL.
Phenethylamine derivatives and intermediates therefor
申请人:AMERICAN HOME PRODUCTS CORPORATION
公开号:EP0112669A2
公开(公告)日:1984-07-04
Novel phenethylamine derivatives are central nervous system antidepressants. The compounds are those having the formula
where A is
where the dotted line represents optional unsaturation;
R1 and R7 are, independently, hydrogen or C1 -C6 alkyl;
R2 is C1 -C6 alkyl;
R4 is hydrogen, C1 -C4 alkyl, formyl or C2 -C7 alkanoly;
R5 and R6 are hydrogen or defined substituents and n is 0,1,2,3, or 4 and their pharmaceutically acceptable salts. Novel intermediates for the preparation of these compounds include those of the formulae